White House speaking with Novo Nordisk, Eli Lilly about selling some obesity drugs for $149/mo: WSJ

Group 1 - Novo Nordisk has lowered its full-year profit and revenue forecast due to reduced growth expectations for GLP-1 treatments [1] - The White House is in discussions with Novo Nordisk and Eli Lilly to make obesity drugs available on a proposed government-run website for $149 a month, with Medicare and Medicaid coverage [2] - The obesity market is still considered an unmet need, despite recent advancements in drug development [3]